Megan D. Hoban
Megan D. Hoban
Scientist, Magenta Therapeutics
Verified email at
Cited by
Cited by
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
MD Hoban, GJ Cost, MC Mendel, Z Romero, ML Kaufman, AV Joglekar, ...
Blood 125 (17), 2597-2604, 2015
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
MD Hoban, SH Orkin, DE Bauer
Blood 127 (7), 839-848, 2016
Wild-type adenoviruses from groups A–F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent
DM Appledorn, A Kiang, A McBride, H Jiang, S Seregin, JM Scott, ...
Gene therapy 15 (12), 885-901, 2008
A genome editing primer for the hematologist
MD Hoban, DE Bauer
Blood 127 (21), 2525-2535, 2016
Dissecting the Mechanism of Histone Deacetylase Inhibitors to Enhance the Activity of Zinc Finger Nucleases Delivered by Integrase-Defective Lentiviral Vectors
AV Joglekar, L Stein, M Ho, MD Hoban, RP Hollis, DB Kohn
Human gene therapy 25 (7), 599-608, 2014
CRISPResso: sequencing analysis toolbox for CRISPR genome editing
L Pinello, MC Canver, MD Hoban, SH Orkin, DB Kohn, DE Bauer, ...
bioRxiv, 031203, 2016
The human ankyrin 1 promoter insulator sustains gene expression in a β-globin lentiviral vector in hematopoietic stem cells
Z Romero, B Campo-Fernandez, J Wherley, ML Kaufman, F Urbinati, ...
Molecular Therapy-Methods & Clinical Development 2, 15012, 2015
Delivery of genome editing reagents to hematopoietic stem/progenitor cells
MD Hoban, Z Romero, GJ Cost, M Mendel, M Holmes, DB Kohn
Current protocols in stem cell biology, 5B. 4.1-5B. 4.10, 2016
The system can't perform the operation now. Try again later.
Articles 1–8